Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P12036
UPID:
NFH_HUMAN
Alternative names:
200 kDa neurofilament protein; Neurofilament triplet H protein
Alternative UPACC:
P12036; B4DYY4; Q96HF8; Q9UJS7; Q9UQ14
Background:
Neurofilament heavy polypeptide (NEFH), also known as the 200 kDa neurofilament protein, plays a crucial role in the maintenance of neuronal caliber alongside NEFL and NEFM. It is part of the neurofilament triplet proteins and is essential in mature axons, working in concert with PRPH and INA to form neuronal networks.
Therapeutic significance:
NEFH's involvement in Amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease, axonal, 2CC, highlights its potential as a target for therapeutic intervention. Understanding the role of NEFH could open doors to potential therapeutic strategies.